[Optimization of hypotensive therapy in hypertensive patients with new beta-1 selective long-acting adrenoblocker]

Area of Science:

• Cardiovascular Pharmacology
• Hypertension Management
• Hemodynamic Monitoring

Background:

• Hypertension is a prevalent cardiovascular condition requiring effective therapeutic strategies.
• Understanding the hemodynamic profile of hypertensive patients is crucial for targeted treatment.
• Beta-1-adrenoblockers represent a class of drugs used in managing high blood pressure.

Purpose of the Study:

• To evaluate the therapeutic response of Kerlon (a beta-1-adrenoblocker) in hypertensive subjects.
• To assess the impact of Kerlon on central hemodynamics.
• To determine if the hemodynamic response to Kerlon is dependent on the initial hemocirculation type.

Main Methods:

• Central hemodynamics were measured using tetrapolar chest rheography.
• Therapeutic efficacy was assessed through hemodynamic indices and an acute pharmacological test.
• Twenty hypertensive subjects participated in the clinical trial.

Main Results:

• The blood pressure-lowering effect of Kerlon was dependent on the initial hemocirculation type.
• In hyperkinetic hemodynamics, blood pressure reduction was associated with a diminished cardiac index.
• In eukinetic and hypokinetic types, Kerlon decreased total peripheral vascular resistance, leading to lower blood pressure.

Conclusions:

• Kerlon demonstrates therapeutic efficacy in hypertension, with its mechanism varying by hemodynamic profile.
• The study highlights the importance of individualized hemodynamic assessment for optimizing beta-1-adrenoblocker therapy.
• Kerlon's effectiveness is linked to its ability to modulate cardiac output or peripheral resistance based on the patient's baseline hemodynamics.